PDCD1 and gastric cancer: The Gemini study (an open-label, multicenter, phase II study) is investigating the role of rilvegostomig, a bispecific humanized IgG1 mAb against PD-1 and TIGIT, in combination with SoC chemotherapy, CAPOX (oxaliplatin + capecitabine) or FOLFOX (oxaliplatin + 5-FU + folinic acid), in patients with locally advanced, unresectable or metastatic GC.